Merck Bets Big on Oral Cholesterol Treatment to Revive Struggling PCSK9 Market
Merck (MRK) is looking to revive the struggling PCSK9 inhibitor market with its newly developed oral cholesterol treatment, Lipfendra. The drug class was once hailed as a breakthrough in cardiovascular care and cholesterol management, but existing injectable PCSK9 drugs have underperformed commercial expectations.
The primary issue has been the delivery method, which requires injection and can deter patients and limit prescriptions. Merck believes its oral pill format could fundamentally change patient uptake by providing stronger adherence, greater comfort, and a lower psychological barrier to treatment.
Merck is counting on regulatory support and physician enthusiasm to help Lipfendra achieve what its injectable predecessors could not. The company frames Lipfendra as a potential turning point for the PCSK9 inhibitor class, which has struggled to fulfill its early promise in treating millions of patients worldwide with uncontrolled cholesterol levels.